{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:54:11Z","timestamp":1774425251888,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T00:00:00Z","timestamp":1379462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s12012-013-9224-0","type":"journal-article","created":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T19:16:56Z","timestamp":1379445416000},"page":"413-425","source":"Crossref","is-referenced-by-count":31,"title":["Therapeutic Concentrations of Mitoxantrone Elicit Energetic Imbalance in H9c2 Cells as an Earlier Event"],"prefix":"10.1007","volume":"13","author":[{"given":"Luciana Grazziotin","family":"Rossato","sequence":"first","affiliation":[]},{"given":"Vera Marisa","family":"Costa","sequence":"additional","affiliation":[]},{"given":"V\u00e2nia","family":"Vilas-Boas","sequence":"additional","affiliation":[]},{"given":"Maria","family":"de Lourdes Bastos","sequence":"additional","affiliation":[]},{"given":"Anabela","family":"Rolo","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Palmeira","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Remi\u00e3o","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,9,18]]},"reference":[{"key":"9224_CR1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/14740338.4.2.219","volume":"4","author":"K Seiter","year":"2005","unstructured":"Seiter, K. (2005). Toxicity of the topoisomerase II inhibitors. Expert Opinion on Drug Safety, 4, 219\u2013234.","journal-title":"Expert Opinion on Drug Safety"},{"key":"9224_CR2","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/WNL.0b013e3181e0f7e6","volume":"74","author":"E Kingwell","year":"2010","unstructured":"Kingwell, E., Koch, M., Leung, B., Isserow, S., Geddes, J., Rieckmann, P., et al. (2010). Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology, 74, 1822\u20131826.","journal-title":"Neurology"},{"key":"9224_CR3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/BSR20090119","volume":"30","author":"SN Khan","year":"2010","unstructured":"Khan, S. N., Lai, S. K., Kumar, P., & Khan, A. U. (2010). Effect of mitoxantrone on proliferation dynamics and cell cycle progression. Bioscience Reports, 30, 375\u2013381.","journal-title":"Bioscience Reports"},{"key":"9224_CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijbiomac.2010.10.002","volume":"48","author":"Z Hajihassan","year":"2011","unstructured":"Hajihassan, Z., & Rabbani-Chadegani, A. (2011). Interaction of mitoxantrone, as an anticancer drug, with chromatin proteins, core histones and H1, in solution. International Journal of Biological Macromolecules, 48, 87\u201392.","journal-title":"International Journal of Biological Macromolecules"},{"key":"9224_CR5","first-page":"194","volume":"52","author":"PM Alderton","year":"1992","unstructured":"Alderton, P. M., Gross, J., & Green, M. D. (1992). Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Research, 52, 194\u2013201.","journal-title":"Cancer Research"},{"key":"9224_CR6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/03602538608998294","volume":"17","author":"VK Batra","year":"1986","unstructured":"Batra, V. K., Morrison, J. A., Woodward, D. L., Siverd, N. S., & Yacobi, A. (1986). Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metabolism Reviews, 17, 311\u2013329.","journal-title":"Drug Metabolism Reviews"},{"key":"9224_CR7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12094-008-0150-8","volume":"10","author":"M Sereno","year":"2008","unstructured":"Sereno, M., Brunello, A., Chiappori, A., Barriuso, J., Casado, E., Belda, C., et al. (2008). Cardiac toxicity: Old and new issues in anti-cancer drugs. Clinical and Translational Oncology, 10, 35\u201346.","journal-title":"Clinical and Translational Oncology"},{"key":"9224_CR8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1034\/j.1600-0773.2003.930301.x","volume":"93","author":"KB Wallace","year":"2003","unstructured":"Wallace, K. B. (2003). Doxorubicin-induced cardiac mitochondrionopathy. Pharmacology and Toxicology, 93, 105\u2013115.","journal-title":"Pharmacology and Toxicology"},{"key":"9224_CR9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.biochi.2010.09.015","volume":"93","author":"TB Br\u00fcck","year":"2011","unstructured":"Br\u00fcck, T. B., & Br\u00fcck, D. W. (2011). Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidase. Biochimie, 93, 217\u2013226.","journal-title":"Biochimie"},{"key":"9224_CR10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/bjc.1989.314","volume":"60","author":"SJ Duthie","year":"1989","unstructured":"Duthie, S. J., & Grant, M. H. (1989). The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells. British Journal of Cancer, 60, 566\u2013571.","journal-title":"British Journal of Cancer"},{"key":"9224_CR11","first-page":"593","volume":"10","author":"C Panousis","year":"1995","unstructured":"Panousis, C., Kettle, A., & Phillips, D. R. (1995). Myeloperoxidase oxidises mitoxantrone to metabolites which bind covalently DNA and RNA. Anticancer drug designer, 10, 593\u2013605.","journal-title":"Anticancer drug designer"},{"key":"9224_CR12","first-page":"5135","volume":"53","author":"K Mewes","year":"1993","unstructured":"Mewes, K., Blanz, J., Ehninger, G., Gebhardt, R., & Zeller, K. P. (1993). Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Research, 53, 5135\u20135142.","journal-title":"Cancer Research"},{"key":"9224_CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0009-2797(94)03603-6","volume":"97","author":"SJ Li","year":"1995","unstructured":"Li, S. J., Rodgers, E. H., & Grant, M. H. (1995). The activity of xenobiotic enzymes and the cytotoxicity of mitoxantrone in MCF 7 human breast cancer cells treated with inducing agents. Chemico Biological Interactions, 97, 101\u2013118.","journal-title":"Chemico Biological Interactions"},{"key":"9224_CR14","doi-asserted-by":"crossref","unstructured":"Rossato, L., Costa, V., De Pinho, P., Freitas, V., Viloune, L., Bastos, M., et al. (2013). The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity. Archives of Toxicology. doi: 10.1007\/s00204-013-1040-6 .","DOI":"10.1007\/s00204-013-1040-6"},{"key":"9224_CR15","first-page":"550","volume":"53","author":"NG Shipp","year":"1993","unstructured":"Shipp, N. G., Dorr, R. T., Alberts, D. S., Dawson, B. V., & Hendrix, M. (1993). Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Research, 53, 550\u2013556.","journal-title":"Cancer Research"},{"key":"9224_CR16","first-page":"361","volume":"71","author":"E Bachmann","year":"1987","unstructured":"Bachmann, E., Weber, E., & Zbinden, G. (1987). Effect of mitoxantrone and doxorubicin on energy metabolism of the rat heart. Cancer Treatment Reports, 71, 361\u2013366.","journal-title":"Cancer Treatment Reports"},{"key":"9224_CR17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0014-4827(76)90447-X","volume":"98","author":"BW Kimes","year":"1976","unstructured":"Kimes, B. W., & Brandt, B. L. (1976). Properties of a clonal muscle from rat heart. Experimental Cell Research, 98, 367\u2013381.","journal-title":"Experimental Cell Research"},{"key":"9224_CR18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.vascn.2007.06.001","volume":"56","author":"BNM Zordoky","year":"2007","unstructured":"Zordoky, B. N. M., & El-Kadi, A. O. S. (2007). H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. Journal of Pharmacological and Toxicological Methods, 56, 317\u2013322.","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"9224_CR19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.tox.2008.12.010","volume":"257","author":"VM Costa","year":"2009","unstructured":"Costa, V. M., Silva, R., Ferreira, R., Amado, F., Carvalho, F., Bastos, M. L., et al. (2009). Adrenaline in pro-oxidant conditions elicits intracellular survival pathways in isolated rat cardiomyocytes. Toxicology, 257, 70\u201379.","journal-title":"Toxicology"},{"key":"9224_CR20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00204-010-0630-9","volume":"85","author":"LG Rossato","year":"2011","unstructured":"Rossato, L. G., Costa, V. M., De Pinho, P. G., Carvalho, F., Bastos, M. L., & Remi\u00e3o, F. (2011). Structural isomerization of synephrine influences its uptake and ensuing glutathione depletion in rat-isolated cardiomyocytes. Archives of Toxicology, 85, 929\u2013939.","journal-title":"Archives of Toxicology"},{"key":"9224_CR21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/phrs.1998.0438","volume":"39","author":"MM Sayed-Ahmed","year":"1999","unstructured":"Sayed-Ahmed, M. M., Shaarawy, S., Shouman, S. A., & Osman, A. M. (1999). Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacological Research, 39, 289\u2013295.","journal-title":"Pharmacological Research"},{"key":"9224_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biochi.2006.09.006","volume":"89","author":"C Angeloni","year":"2007","unstructured":"Angeloni, C., Spencer, J. P. E., Leoncini, E., Biagi, P. L., & Hrelia, S. (2007). Role of quercetin and its in vivo metabolites in protecting H9c2 cells against oxidative stress. Biochimie, 89, 73\u201382.","journal-title":"Biochimie"},{"key":"9224_CR23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jpba.2006.07.030","volume":"43","author":"D Grotto","year":"2007","unstructured":"Grotto, D., Santa Maria, L. D., Boeira, S., Valentini, J., Char\u00e3o, M. F., Moro, A. M., et al. (2007). Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. Journal of Pharmaceutical and Biomedical Analysis, 43, 619\u2013624.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"9224_CR24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1021\/tx7000916","volume":"20","author":"VM Costa","year":"2007","unstructured":"Costa, V. M., Silva, R., Ferreira, L. M., Branco, P. S., Carvalho, F., Bastos, M. L., et al. (2007). Oxidation process of adrenaline in freshly isolated rat cardiomyocytes: Formation of adrenochrome, quinoproteins, and GSH adduct. Chemical Research in Toxicology, 20, 1183\u20131191.","journal-title":"Chemical Research in Toxicology"},{"key":"9224_CR25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1020193906974","volume":"19","author":"D Floryk","year":"1999","unstructured":"Floryk, D., & Houst\u0115k, J. (1999). Tetramethyl rhodamine methyl ester (TMRM) is suitable for cytofluorometric measurements of mitochondrial membrane potential in cells treated with digitonin. Bioscience Reports, 19, 27\u201334.","journal-title":"Bioscience Reports"},{"key":"9224_CR26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1021\/tx049960f","volume":"17","author":"M Carvalho","year":"2004","unstructured":"Carvalho, M., Remi\u00e3o, F., Milhazes, N., Borges, F., Fernandes, E., Monteiro, M. D. C., et al. (2004). Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chemical Research in Toxicology, 17, 623\u2013632.","journal-title":"Chemical Research in Toxicology"},{"key":"9224_CR27","first-page":"4850","volume":"53","author":"P Canal","year":"1993","unstructured":"Canal, P., Attal, M., Chatelut, E., Guichard, S., Huguet, F., Muller, C., et al. (1993). Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Research, 53, 4850\u20134854.","journal-title":"Cancer Research"},{"key":"9224_CR28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pharmthera.2005.07.002","volume":"109","author":"O Neuhaus","year":"2006","unstructured":"Neuhaus, O., Kieseier, B. C., & Hartung, H.-P. (2006). Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacology & Therapeutics, 109, 198\u2013209.","journal-title":"Pharmacology & Therapeutics"},{"key":"9224_CR29","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/sj.onc.1207936","volume":"23","author":"J Kluza","year":"2004","unstructured":"Kluza, J., Marchetti, P., Gallego, M.-A., Lancel, S., Fournier, C., Loyens, A., et al. (2004). Mitochondrial proliferation during apoptosis induced by anticancer agents: Effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene, 23, 7018\u20137030.","journal-title":"Oncogene"},{"key":"9224_CR30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00685596","volume":"30","author":"GR Fisher","year":"1992","unstructured":"Fisher, G. R., & Patterson, L. H. (1992). Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin. Cancer Chemotherapy and Pharmacology, 30, 451\u2013458.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9224_CR31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1152\/japplphysiol.00068.2012","volume":"113","author":"F Chen","year":"2012","unstructured":"Chen, F., Lewis, W., Hollander, J. M., Baseler, W., & Finkel, M. S. (2012). N-acetylcysteine reverses cardiac myocyte dysfunction in HIV-Tat proteinopathy. Journal of Applied Physiology, 113, 105\u2013113.","journal-title":"Journal of Applied Physiology"},{"key":"9224_CR32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1152\/japplphysiol.01471.2012","volume":"115","author":"F Chen","year":"2013","unstructured":"Chen, F., Hadfield, J., Berzingi, C., Hollander, J., Miller, D., Nichols, C., et al. (2013). N-acetylcysteine reverses cardiac myocyte dysfunction in a rodent model of behavioral stress. Journal of Applied Physiology, 115, 514\u2013524.","journal-title":"Journal of Applied Physiology"},{"key":"9224_CR33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0300-483X(93)90135-F","volume":"77","author":"SL Arnaiz","year":"1993","unstructured":"Arnaiz, S. L., & Llesuy, S. (1993). Oxidative stress in mouse heart by antitumoral drugs: A comparative study of doxorubicin and mitoxantrone. Toxicology, 77, 31\u201338.","journal-title":"Toxicology"},{"key":"9224_CR34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00174155","volume":"3","author":"RF Novak","year":"1985","unstructured":"Novak, R. F., & Kharasch, E. D. (1985). Mitoxantrone: Propensity for free radical formation and lipid peroxidation-implications for cardiotoxicity. Investigational New Drugs, 3, 95\u201399.","journal-title":"Investigational New Drugs"},{"key":"9224_CR35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.pathol.1.110304.100218","volume":"1","author":"Z Dong","year":"2006","unstructured":"Dong, Z., Saikumar, P., Weinberg, J. M., & Venkatachalam, M. A. (2006). Calcium in cell injury and death. Annual Review of Pathology: Mechanisms of Disease, 1, 405\u2013434.","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"key":"9224_CR36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbrc.2009.08.022","volume":"388","author":"R Li","year":"2009","unstructured":"Li, R., Beebe, T., Cui, J., Rouhanizadeh, M., Ai, L., Wang, P., et al. (2009). Pulsatile shear stress increased mitochondrial membrane potential: Implication of Mn-SOD. Biochemical and Biophysical Research Communications, 388, 406\u2013412.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"9224_CR37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/molehr\/gah004","volume":"10","author":"BM Acton","year":"2004","unstructured":"Acton, B. M. (2004). Alterations in mitochondrial membrane potential during preimplantation stages of mouse and human embryo development. Molecular Human Reproduction, 10, 23\u201332.","journal-title":"Molecular Human Reproduction"},{"key":"9224_CR38","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.addr.2009.04.024","volume":"61","author":"VA Zammit","year":"2009","unstructured":"Zammit, V. A., Ramsay, R. R., Bonomini, M., & Arduini, A. (2009). Carnitine, mitochondrial function and therapy. Advanced Drug Delivery Reviews, 61, 1353\u20131362.","journal-title":"Advanced Drug Delivery Reviews"},{"key":"9224_CR39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(01)01158-X","volume":"425","author":"A Mijares","year":"2001","unstructured":"Mijares, A., & L\u00f3pez, J. R. (2001). L-carnitine prevents increase in diastolic [Ca2+] induced by doxorubicin in cardiac cells. European Journal of Pharmacology, 425, 117\u2013120.","journal-title":"European Journal of Pharmacology"},{"key":"9224_CR40","first-page":"3483","volume":"41","author":"R Newman","year":"1981","unstructured":"Newman, R., Hacker, M., & Krakoff, I. (1981). Amelioration of adriamycin and daunorubicin myocardial toxicity by adenosine. Cancer Research, 41, 3483\u20133488.","journal-title":"Cancer Research"},{"key":"9224_CR41","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2174\/092986711795656081","volume":"18","author":"VM Costa","year":"2011","unstructured":"Costa, V. M., Carvalho, F., Bastos, M. L., Carvalho, R. A., Carvalho, M., & Remi\u00e3o, F. (2011). Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Current Medical Chemistry, 18,\u00a02272\u20132314.","journal-title":"Current Medical Chemistry"},{"key":"9224_CR42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1096\/fasebj.9.2.7781924","volume":"9","author":"BF Trump","year":"1995","unstructured":"Trump, B. F., & Berezesky, I. K. (1995). Calcium-mediated cell injury and cell death. FASEB, 9, 219\u2013228.","journal-title":"FASEB"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-013-9224-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-013-9224-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-013-9224-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T04:59:45Z","timestamp":1563944385000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-013-9224-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,18]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["9224"],"URL":"https:\/\/doi.org\/10.1007\/s12012-013-9224-0","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,18]]}}}